AU2020310107A1 - Antimicrobial, bacteriophage-derived polypeptides and their use against gram-negative and acid-fast bacteria - Google Patents

Antimicrobial, bacteriophage-derived polypeptides and their use against gram-negative and acid-fast bacteria Download PDF

Info

Publication number
AU2020310107A1
AU2020310107A1 AU2020310107A AU2020310107A AU2020310107A1 AU 2020310107 A1 AU2020310107 A1 AU 2020310107A1 AU 2020310107 A AU2020310107 A AU 2020310107A AU 2020310107 A AU2020310107 A AU 2020310107A AU 2020310107 A1 AU2020310107 A1 AU 2020310107A1
Authority
AU
Australia
Prior art keywords
seq
chp
gram
bacteria
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020310107A
Other languages
English (en)
Inventor
Raymond Schuch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Contrafect Corp
Original Assignee
Contrafect Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Contrafect Corp filed Critical Contrafect Corp
Publication of AU2020310107A1 publication Critical patent/AU2020310107A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/711Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00Bacteriophages
    • C12N2795/00011Details
    • C12N2795/14011Details ssDNA Bacteriophages
    • C12N2795/14211Microviridae
    • C12N2795/14222New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2020310107A 2019-07-05 2020-07-02 Antimicrobial, bacteriophage-derived polypeptides and their use against gram-negative and acid-fast bacteria Abandoned AU2020310107A1 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201962870908P 2019-07-05 2019-07-05
US62/870,908 2019-07-05
US201962892783P 2019-08-28 2019-08-28
US62/892,783 2019-08-28
US201962911900P 2019-10-07 2019-10-07
US62/911,900 2019-10-07
US201962948052P 2019-12-13 2019-12-13
US62/948,052 2019-12-13
US202062964743P 2020-01-23 2020-01-23
US62/964,743 2020-01-23
PCT/US2020/040714 WO2021007107A1 (en) 2019-07-05 2020-07-02 Antimicrobial, bacteriophage-derived polypeptides and their use against gram-negative and acid-fast bacteria

Publications (1)

Publication Number Publication Date
AU2020310107A1 true AU2020310107A1 (en) 2022-01-20

Family

ID=74114204

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020310107A Abandoned AU2020310107A1 (en) 2019-07-05 2020-07-02 Antimicrobial, bacteriophage-derived polypeptides and their use against gram-negative and acid-fast bacteria

Country Status (11)

Country Link
US (1) US20220401514A1 (https=)
EP (1) EP3993821A4 (https=)
JP (1) JP2022539383A (https=)
KR (1) KR20220029746A (https=)
CN (1) CN114401735A (https=)
AU (1) AU2020310107A1 (https=)
BR (1) BR112021025948A2 (https=)
CA (1) CA3145990A1 (https=)
IL (1) IL289412A (https=)
MX (1) MX2021015563A (https=)
WO (1) WO2021007107A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210330738A1 (en) * 2018-03-29 2021-10-28 Contrafect Corporation Antimicrobial, bacteriophage-derived polypeptides and their use against gram-negative bacteria
EP3902457A1 (en) * 2018-12-27 2021-11-03 Johnson & Johnson Consumer Inc. Device and method for selective application of topical composition using dynamic threshold values
WO2022032273A1 (en) 2020-08-03 2022-02-10 Johnson & Johnson Consumer Inc. System and method for selective application of cosmetic composition to impart undereye brightening
WO2022204280A1 (en) * 2021-03-26 2022-09-29 Contrafect Corporation Amurins lysins, and lysin-antimicrobial peptide (amp) constructs active against gram-negative bacteria
CN121445856A (zh) * 2025-10-24 2026-02-03 中国农业科学院生物技术研究所 溶菌酶及其衍生的抗菌肽和在制备抑菌药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5741697A (en) * 1995-11-30 1998-04-21 University Of Rochester Bacteriophage of chlamydia psittaci
CA2447823A1 (en) * 2001-05-23 2002-11-28 The University Of British Columbia Diagnosis of vascular disease susceptibility using bacteriophage phi-cpn1 host chlamydia
DK2445515T3 (en) * 2009-06-26 2016-07-04 Univ Leuven Kath antimicrobial agents
CN112368376A (zh) * 2018-03-29 2021-02-12 康特拉费克特公司 溶素-抗微生物肽(amp)多肽构建体、溶素、其分离的编码多核苷酸及其用途
US20210330738A1 (en) * 2018-03-29 2021-10-28 Contrafect Corporation Antimicrobial, bacteriophage-derived polypeptides and their use against gram-negative bacteria
WO2020046747A1 (en) * 2018-08-23 2020-03-05 Contrafect Corporation Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof

Also Published As

Publication number Publication date
US20220401514A1 (en) 2022-12-22
JP2022539383A (ja) 2022-09-08
WO2021007107A1 (en) 2021-01-14
CA3145990A1 (en) 2021-01-14
BR112021025948A2 (pt) 2022-02-08
EP3993821A4 (en) 2023-07-19
EP3993821A1 (en) 2022-05-11
MX2021015563A (es) 2022-03-17
CN114401735A (zh) 2022-04-26
IL289412A (en) 2022-02-01
KR20220029746A (ko) 2022-03-08

Similar Documents

Publication Publication Date Title
US20240018192A1 (en) Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof
US20220402984A1 (en) Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof
US20210147498A1 (en) Use of gram-negative lysin-antimicrobial peptide (amp) polypeptide constructs in pulmonary surfactant and biofilms
US20220401514A1 (en) Antimicrobial, bacteriophage-derived polypeptides and their use against gram-negative and acid-fast bacteria
US20210330738A1 (en) Antimicrobial, bacteriophage-derived polypeptides and their use against gram-negative bacteria
US20210324359A1 (en) Use of gram-negative lysin-antimicrobial peptide (amp) polypeptide constructs in treating endocarditis
US20240181022A1 (en) Amurins lysins, and lysin-antimicrobial peptide (amp) constructs active against gram-negative bacteria
US20220411473A1 (en) Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof
CA3095473A1 (en) Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof
RU2804774C2 (ru) Происходящие из бактериофагов противомикробные полипептиды и их применение против грамотрицательных бактерий